Self-Monitoring Practices and Use of Self-Monitoring Technologies by People with Rheumatic and Musculoskeletal Diseases: An International Survey Study.

Autor:	Matias P; Fraunhofer Portugal AICOS, Rua Alfredo Allen 455/461, 4200-135 Porto, Portugal., Rêgo S; Fraunhofer Portugal AICOS, Rua Alfredo Allen 455/461, 4200-135 Porto, Portugal., Nunes F; Fraunhofer Portugal AICOS, Rua Alfredo Allen 455/461, 4200-135 Porto, Portugal., Araújo R; Fraunhofer Portugal AICOS, Rua Alfredo Allen 455/461, 4200-135 Porto, Portugal., Kartschmit N; Center for Medical Data Science, Institute of Outcomes Research, Medical University of Vienna, 1090 Vienna, Austria., Wilhelmer TC; Österreichische Rheumaliga, 5761 Maria Alm, Austria., Stamm T; Center for Medical Data Science, Institute of Outcomes Research, Medical University of Vienna, 1090 Vienna, Austria., Studenic P; Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, 1090 Vienna, Austria.; Division of Rheumatology, Department of Medicine (Solna), Karolinska Institutet, 171 77 Stockholm, Sweden.
Jazyk:	angličtina
Zdroj:	Healthcare (Basel, Switzerland) [Healthcare (Basel)] 2024 Oct 01; Vol. 12 (19). Date of Electronic Publication: 2024 Oct 01.
DOI:	10.3390/healthcare12191960
Abstrakt:	Background/objectives: Digital health applications (DHAs) promise to improve disease self-management, but adherence remains suboptimal. We aimed to explore self-monitoring practices of rheumatic and musculoskeletal diseases (RMD) patients. A web-survey was conducted over 7 months including RMD patients to study their self-monitoring practices and the potential of DHAs. Methods: Health, sociodemographic, and technology adherence indicators were retrieved for comparison. Regression analyses and unsupervised profiling were performed to investigate multiple patient profiles. Results: From 228 responses gathered, most reported willingness to use DHAs to monitor their condition (78% agreement), although the majority rarely/never tracked symptoms (64%), often due to stable condition or no perceived value (62%). Of those tracking regularly, 52% used non-digital means. Participants with regular self-monitoring practices were more open to use a self-monitoring app (OR = 0.8 [0.6, 0.9]; p = 0.008) and be embedded in multidisciplinary care (OR = 1.4 [1.1, 1.6]; p < 0.001), but showed worse health status (g = 0.4; p = 0.006). Cluster analyses revealed three distinct groups of reasons for not tracking regularly (χ2 = 174.4; p < 0.001), two characterised by perceived low disease activity. Conclusions: Effective use of DHAs remains limited and non-digital means prevail in symptom monitoring. Findings suggest that better patient engagement strategies and passive monitoring should be adopted in early development stages of DHAs for better long-term disease self-care.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu